[
  {
    "ts": "2026-01-14T00:25:19+00:00",
    "headline": "JPM26: Madrigal seeks early dominance in MASH through strategic acquisitions",
    "summary": "Madrigal’s strategy of pursuing combination therapies while the market remains in its infancy could intrinsically link its brand to MASH treatment.",
    "url": "https://www.pharmaceutical-technology.com/analyst-comment/jpm26-madrigal-seeks-early-dominance-in-mash-through-strategic-acquisitions/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "7ef67d1e-15c9-3391-8222-77aac99c5cba",
      "content": {
        "id": "7ef67d1e-15c9-3391-8222-77aac99c5cba",
        "contentType": "STORY",
        "title": "JPM26: Madrigal seeks early dominance in MASH through strategic acquisitions",
        "description": "",
        "summary": "Madrigal’s strategy of pursuing combination therapies while the market remains in its infancy could intrinsically link its brand to MASH treatment.",
        "pubDate": "2026-01-14T00:25:19Z",
        "displayTime": "2026-01-14T00:25:19Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/d2c9274f5695e664713654677740630d",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/t9CznWdnwspHj8MmtfRgog--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/d2c9274f5695e664713654677740630d.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/nEaOatGr_XKpdmA54Bj9uA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/d2c9274f5695e664713654677740630d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/analyst-comment/jpm26-madrigal-seeks-early-dominance-in-mash-through-strategic-acquisitions/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jpm26-madrigal-seeks-early-dominance-002519264.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MDGL"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-14T02:04:44+00:00",
    "headline": "Amneal Pharmaceuticals Eyes 2026 Growth at JPMorgan, Crexont Sales Seen Doubling in 2025",
    "summary": "Amneal Pharmaceuticals (NASDAQ:AMRX) used a presentation and Q&A session at the JPMorgan conference to outline its ongoing shift toward higher-value “affordable medicines” and specialty products, while highlighting near-term growth drivers across complex generics, biosimilars, and branded neurol",
    "url": "https://www.marketbeat.com/instant-alerts/amneal-pharmaceuticals-eyes-2026-growth-at-jpmorgan-crexont-sales-seen-doubling-in-2025-2026-01-13/?utm_source=yahoofinance&utm_medium=yahoofinance",
    "source": "MarketBeat",
    "provider": "yfinance",
    "raw": {
      "id": "56d1de44-f370-37b6-a283-4b5f579518fb",
      "content": {
        "id": "56d1de44-f370-37b6-a283-4b5f579518fb",
        "contentType": "STORY",
        "title": "Amneal Pharmaceuticals Eyes 2026 Growth at JPMorgan, Crexont Sales Seen Doubling in 2025",
        "description": "",
        "summary": "Amneal Pharmaceuticals (NASDAQ:AMRX) used a presentation and Q&A session at the JPMorgan conference to outline its ongoing shift toward higher-value “affordable medicines” and specialty products, while highlighting near-term growth drivers across complex generics, biosimilars, and branded neurol",
        "pubDate": "2026-01-14T02:04:44Z",
        "displayTime": "2026-01-14T02:04:44Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/marketbeat_955/ae2eb0de87b5c241b29635b9ec95e87a",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "Amneal Pharmaceuticals logo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jFulpYr9v8ZnEo4JVHaKiw--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketbeat_955/ae2eb0de87b5c241b29635b9ec95e87a.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/HlM2YERRMcU3GVpFfFKbPQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/marketbeat_955/ae2eb0de87b5c241b29635b9ec95e87a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MarketBeat",
          "url": "https://www.marketbeat.com/"
        },
        "canonicalUrl": {
          "url": "https://www.marketbeat.com/instant-alerts/amneal-pharmaceuticals-eyes-2026-growth-at-jpmorgan-crexont-sales-seen-doubling-in-2025-2026-01-13/?utm_source=yahoofinance&utm_medium=yahoofinance",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/amneal-pharmaceuticals-eyes-2026-growth-020444909.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMRX"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]